[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370196-105":59,"doc-detail-370196-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","fingolimod-and-risk-of-skin-cancer-among-individuals-with-multiple-sclerosis-a-population-based-cohort-study-protocol","Fingolimod and risk of skin cancer among individuals with multiple sclerosis - a population-based cohort study protocol","","Protocol describing how to investigate the association between fingolimod exposure and skin cancer incidence in people with multiple sclerosis (MS). The study uses population-based administrative health data from two Canadian provinces to run an observational “trial emulation” cohort with an active comparator and new-user design. Adults (≥18) with MS will be identified via a validated algorithm; incident users of fingolimod and comparators will be followed for melanoma and non-melanoma outcomes using survival analysis with hazard ratios adjusted for confounders.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/fingolimod-and-risk-of-skin-cancer-among-individuals-with-multiple-sclerosis-a-population-based-cohort-study-protocol/370196/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/fingolimod-and-risk-of-skin-cancer-among-individuals-with-multiple-sclerosis-a-population-based-cohort-study-protocol/370196.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the primary goal of this study protocol?","Question",{"text":112,"@type":113},"To describe a protocol for investigating the relationship between fingolimod use and the incidence of skin cancer in individuals with multiple sclerosis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How will participants and exposures be identified?",{"text":117,"@type":113},"Adults (≥18 years) with MS will be identified using a validated algorithm, and incident users of fingolimod and active comparators will be identified for follow-up.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes and statistical approach will be used?",{"text":121,"@type":113},"Skin cancer outcomes include melanoma and non-melanoma skin cancers, with survival analysis used to estimate hazard ratios and 95% confidence intervals adjusted for potential confounders.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370196,1791414712,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Open access Protocol  \n Fingolimod and risk of skin cancer  \namong individuals with multiple sclerosis: a population-based cohort study protocol  \nAnalisa Jia,1,2 Lisa Kuramoto,3 Amir Khakban,1 Weng Sut Sio,1  \nAnthony Traboulsee,4 M A De Vera  ,1,5 Jiwon Oh,6 Jonathan Loree,7 Roger Tam,8 Larry D Lynd,1,5 Jacquelyn J Cragg  1,2  \nTo cite: Jia A, Kuramoto L, Khakban A, et al. Fingolimod and risk of skin cancer among individuals with multiple sclerosis: a population-based cohort study protocol. BMJ Open 2025;15:e088924 . doi:10 . 1136/ bmjopen-2024-088924  \n► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[bmjopen-2024-088924](bmjopen-2024-088924)) .  \nReceived 17 May 2024  \nAccepted 16 December 2024  \n© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Jacquelyn J Cragg; [jacquelyn.cragg@icord.org](jacquelyn.cragg@icord.org)  \nABSTRACT  \nIntroduction Long-term population-based safety studies, applying advanced causal inference techniques, including an active comparator with new-user design, are needed to investigate skin cancer outcomes among individuals with multiple sclerosis (MS) treated with fingolimod. This study aims to describe a protocol for investigating the relationship between fingolimod use and the incidence of skin cancer among individuals with MS.  \nMethods and analysis We will use population-based administrative health data from two Canadian provinces (British Columbia and Alberta) to conduct an observational cohort ‘trial emulation’ study with an active comparator and new-user design. Individuals with MS aged ≥18 years will be identified using a validated algorithm. Incident users of fingolimod and active comparators (natalizumab, alemtuzumab, dimethyl fumarate, teriflunomide) will then be identified. The outcome of interest will be skin cancer (melanoma and non-melanoma skin cancers) . Survival analysis will be used to estimate HRs and corresponding 95% CIs, adjusted for potential confounders.  \nEthics and dissemination Ethics approval for this study was obtained from the University of British Columbia Clinical Research Ethics Board (H24-03199) . No personal identifying information will be made available as part of this study. Findings will be disseminated through presentations and peer-reviewed publications.  \nTrial registration number NCT06705608.  \nINTRODUCTION  \nMultiple sclerosis (MS) is a chronic autoimmune disorder that affects the central nervous system (CNS), including the brain, spinal cord and optic nerves.1 2 MS occurs when the immune system mistakenly attacks the myelin sheath that covers and protects nerve fibres, causing scarring and disruption of nerve signals.3 Symptoms of MS can vary widely depending on the location and extent of nerve damage. Common signs and symptoms include fatigue, muscle weakness, spasticity, difficulty with coordination and balance, cognitive impairment, vision  \nSTRENGTHS AND LIMITATIONS OF THIS STUDY   \n⇒ A population-based cohort study on drug safety and skin cancer among patients with multiple sclerosis.  \n⇒ A trial emulation approach, including a new-user and an active comparator design.  \n⇒ Observational analogues of intention-to-treat and per-protocol analyses to estimate the effect of treatment strategy assignment and the effect of adhering to the treatment strategy.  \n⇒ Potential confounding variables may not be captured by administrative data.  \n⇒ Data on drug dispensations may not correspond to medication usage if adherence is low.  \nproblems and bladder and bowel dysfunction. Typically, MS manifests as a relapsingremitting disease (RRMS); however, as more severe neurological disabilities accumulate over time, th","cbCaicGCEtG3mMrR","https://ap.wps.com/l/cbCaicGCEtG3mMrR","pdf",402613,11,"English","# Abstract\n## Introduction\n## Methods and analysis\n## Ethics and dissemination\n# Strengths and limitations of this study","[{\"question\":\"What is the primary goal of this study protocol?\",\"answer\":\"To describe a protocol for investigating the relationship between fingolimod use and the incidence of skin cancer in individuals with multiple sclerosis.\"},{\"question\":\"How will participants and exposures be identified?\",\"answer\":\"Adults (≥18 years) with MS will be identified using a validated algorithm, and incident users of fingolimod and active comparators will be identified for follow-up.\"},{\"question\":\"What outcomes and statistical approach will be used?\",\"answer\":\"Skin cancer outcomes include melanoma and non-melanoma skin cancers, with survival analysis used to estimate hazard ratios and 95% confidence intervals adjusted for potential confounders.\"}]","Fingolimod and risk of skin cancer among individuals with multiple sclerosis - a population-based cohort study protocol | PDF",1790187287,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff142283227a4c74981eecacc90aaaf6.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1fc0076def3b355e6e2cc4014003f147.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a7a4e371a4157c8a94d37e992711bf1b.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53b24058a608018a8faed82641159a89.webp",980,1306]